Project Grant R21AR088224
Award Date 9/10/26
Completion Date 8/31/28
Dollars Obligated $200K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Leland Stanford Junior University $204,682 on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize the roles of RNA-binding protein assemblies in epidermal homeostasis. The recipient will develop and apply two new crosslinking immunoprecipitation-based methods—IRCLIP-RNP and RE-CLIP—to study how RNA-binding proteins organize and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Leland Stanford Junior University $667,829 on August 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate an osteoinductive, biodegradable intramedullary implant as an adjunctive therapy for distraction osteogenesis in large orthopedic trauma and limb reconstruction. The project addresses a major limitation of the Ilizarov surgical technique—the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Southern California Institute For Research And Education $337,072 on June 19, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into the cellular and molecular mechanisms of CCDC120-associated osteopetrosis, a novel form of X-linked osteopetrosis. The research examines how loss of the CCDC120 gene and its binding partner CYTOHESIN-2 in osteoclast...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $448,563 on September 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for an ancillary study investigating systemic bone loss mechanisms following fracture. UCSF will conduct multimodal analysis of circulating cells and factors in blood samples collected from fracture patients at multiple timepoints...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $2.298 million on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into osteocyte peri-lacunar and canalicular remodeling mechanisms in maternal bone adaptation during pregnancy, lactation, and post-lactation phases. The project investigates how the female skeleton undergoes bone loss and microstructural...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University $148,062 on September 30, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research investigates the mechanism by which epithelial stem and progenitor cells encode inflammatory memory in psoriasis and other remitting-relapsing inflammatory disorders. The study tests whether homeostatic and inflammatory transcription factors dynamically...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $1.696 million to Poly Orth International on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds translational pre-clinical research and development of a 3D-printed skin and bone integrated pylon (SBIP-3D) for direct skeletal attachment of limb prostheses. The technology, developed by Poly Orth International, integrates with both residual bone...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $545,808 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research to develop matrix-modifying therapies that increase cartilage endplate permeability and improve nutrient transport to spinal disc cells. The project addresses the mechanism underlying disc degeneration by investigating...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $117,426 to the University of California, San Diego on June 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a noninvasive MRI method for assessing bone quality in type 2 diabetes patients. The project develops an ultrashort echo time quantitative magnetization transfer (UTE-QMT) MRI technique to measure collagen crosslinking in cortical bone, a bone quality...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...